Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(22):1687-1697; doi:10.1093/jnci/93.22.1687
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Grossmann, M. E.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossmann, M. E.
Right arrow Articles by Tindall, D. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 22, 1687-1697, November 21, 2001
© 2001 Oxford University Press


REVIEW

Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer

Michael E. Grossmann, Haojie Huang, Donald J. Tindall

Affiliations of authors: M. E. Grossmann, H. Huang (Department of Urology), D. J. Tindall (Departments of Urology and Biochemistry/Molecular Biology), Mayo Clinic, Rochester, MN.

Correspondence to: Donald J. Tindall, Ph.D., Departments of Urology and Biochemistry/Molecular Biology, Mayo Clinic, Guggenheim 17, 200 1st St., S.W., Rochester, MN (e-mail: Tindall{at}mayo.edu).

Prostate cancer is the second most prevalent cancer in males in the United States. Standard therapy relies on removing, or blocking the actions of, androgens. In most cases, this therapy results in a regression of the cancer because the prostate and most primary prostate tumors depend on androgens for growth and the avoidance of apoptosis. However, a portion of the cancers eventually relapse, at which point they are termed "androgen refractory" and can no longer be cured by conventional therapy of any type. The precise molecular events that lead from androgen-sensitive prostate cancer to androgen-refractory prostate cancer are, therefore, of great interest. This review seeks to identify specific molecular events that may be linked directly to the progression to androgen-refractory cancer. Some of the mechanisms appear to involve the androgen receptor (AR) directly and include mutations in, or amplification of, the AR gene in a manner that allows the AR to respond to low doses of androgens, other steroids, or antiandrogens. In a less direct manner, coactivators may increase the sensitivity of the AR to androgens and even other nonandrogenic substances through a number of mechanisms. Additional indirect mechanisms that do not result from mutation of the AR may involve activation of the AR by peptide growth factors or cytokines or may involve bypassing the AR entirely via other cellular pathways. Identification of the role of these mechanisms in the progression to androgen-refractory prostate cancer is critical for developing therapies capable of curing this disease.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L. K. Gediya, Z. Guo, H.-B. Fang, V. C.O. Njar, and A. M.H. Brodie
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3{beta}-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Mol. Cancer Ther., August 1, 2008; 7(8): 2348 - 2357.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
W. A. Fritz, T.-M. Lin, and R. E. Peterson
The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates
Carcinogenesis, May 1, 2008; 29(5): 1077 - 1082.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. G. Wang, E. M. Johnson, Y. Kinoshita, J. S. Babb, M. T. Buckley, L. F. Liebes, J. Melamed, X.-M. Liu, R. Kurek, L. Ossowski, et al.
Androgen Receptor Overexpression in Prostate Cancer Linked to Pur{alpha} Loss from a Novel Repressor Complex
Cancer Res., April 15, 2008; 68(8): 2678 - 2688.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
S.-L. Lin, A. Chiang, D. Chang, and S.-Y. Ying
Loss of mir-146a function in hormone-refractory prostate cancer
RNA, March 1, 2008; 14(3): 417 - 424.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein
Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer
Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Hara, H. Miyazaki, A. Lee, C. P. Tran, and R. E. Reiter
Androgen Receptor and Invasion in Prostate Cancer
Cancer Res., February 15, 2008; 68(4): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S.-L. Lin, D. Chang, A. Chiang, and S.-Y. Ying
Androgen receptor regulates CD168 expression and signaling in prostate cancer
Carcinogenesis, February 1, 2008; 29(2): 282 - 290.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. R. Sterbis, C. Gao, B. Furusato, Y. Chen, S. Shaheduzzaman, L. Ravindranath, D. J. Osborn, I. L. Rosner, A. Dobi, D. G. McLeod, et al.
Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival
Clin. Cancer Res., February 1, 2008; 14(3): 758 - 763.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion
Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev., December 1, 2007; 28(7): 778 - 808.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. M. Dehm and D. J. Tindall
Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer
Mol. Endocrinol., December 1, 2007; 21(12): 2855 - 2863.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. V. Heemers, K. M. Regan, S. M. Dehm, and D. J. Tindall
Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer
Cancer Res., November 1, 2007; 67(21): 10592 - 10599.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Lapointe, C. Li, C. P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J. D. Brooks, and J. R. Pollack
Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis
Cancer Res., September 15, 2007; 67(18): 8504 - 8510.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S Darby, J Stockley, M M Khan, C N Robson, H Y Leung, and V J Gnanapragasam
Expression of GnRH type II is regulated by the androgen receptor in prostate cancer
Endocr. Relat. Cancer, September 1, 2007; 14(3): 613 - 624.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
C.-T. Wu, W.-C. Chen, S.-K. Liao, C.-L. Hsu, K.-D. Lee, and M.-F. Chen
The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy
Endocr. Relat. Cancer, September 1, 2007; 14(3): 633 - 643.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
H. Nakauchi, K.-i. Matsuda, I. Ochiai, A. Kawauchi, Y. Mizutani, T. Miki, and M. Kawata
A Differential Ligand-mediated Response of Green Fluorescent Protein-tagged Androgen Receptor in Living Prostate Cancer and Non-prostate Cancer Cell Lines
J. Histochem. Cytochem., June 1, 2007; 55(6): 535 - 544.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Tamura, M. Furihata, T. Tsunoda, S. Ashida, R. Takata, W. Obara, H. Yoshioka, Y. Daigo, Y. Nasu, H. Kumon, et al.
Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles
Cancer Res., June 1, 2007; 67(11): 5117 - 5125.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. P. Mahajan, Y. Liu, S. Majumder, M. R. Warren, C. E. Parker, J. L. Mohler, H. S. Earp, and Y. E. Whang
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
PNAS, May 15, 2007; 104(20): 8438 - 8443.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-C. Yang, Y.-C. Wang, S. Wei, L.-F. Lin, C.-S. Chen, C.-C. Lee, C.-C. Lin, and C.-S. Chen
Peroxisome Proliferator-Activated Receptor {gamma}-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation
Cancer Res., April 1, 2007; 67(7): 3229 - 3238.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Cancer Res., April 1, 2007; 67(7): 3422 - 3430.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Fan, T. Yanase, H. Morinaga, T. Okabe, M. Nomura, H. Daitoku, A. Fukamizu, S. Kato, R. Takayanagi, and H. Nawata
Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor
J. Biol. Chem., March 9, 2007; 282(10): 7329 - 7338.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Dehm and D. J. Tindall
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
J. Biol. Chem., September 22, 2006; 281(38): 27882 - 27893.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q. Xia, J. Sung, W. Chowdhury, C.-l. Chen, N. Hoti, S. Shabbeer, M. Carducci, and R. Rodriguez
Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo.
Cancer Res., July 15, 2006; 66(14): 7237 - 7244.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. S. Lyons and K. L. Burnstein
Vav3, a Rho GTPase Guanine Nucleotide Exchange Factor, Increases during Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity
Mol. Endocrinol., May 1, 2006; 20(5): 1061 - 1072.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
S. Nettikadan, K. Radke, J. Johnson, J. Xu, M. Lynch, C. Mosher, and E. Henderson
Detection and Quantification of Protein Biomarkers from Fewer than 10 Cells
Mol. Cell. Proteomics, May 1, 2006; 5(5): 895 - 901.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. Le, J. T. Arnold, K. K. McFann, and M. R. Blackman
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E952 - E960.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Veeramani, T.-C. Yuan, S.-J. Chen, F.-F. Lin, J. E Petersen, S. Shaheduzzaman, S. Srivastava, R. G MacDonald, and M.-F. Lin
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 805 - 822.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Kim, J. Lapointe, G. Kaygusuz, D. E. Ong, C. Li, M. van de Rijn, J. D. Brooks, and J. R. Pollack
The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Cancer Res., September 15, 2005; 65(18): 8118 - 8124.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall
p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6
Cancer Res., July 1, 2005; 65(13): 5965 - 5973.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Titus, M. J. Schell, F. B. Lih, K. B. Tomer, and J. L. Mohler
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4653 - 4657.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Cancer Res., April 15, 2005; 65(8): 3404 - 3409.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer
Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung
Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Cancer Res., March 15, 2005; 65(6): 2287 - 2295.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J. K Oosterhoff, J A. Grootegoed, and L. J Blok
Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling
Endocr. Relat. Cancer, March 1, 2005; 12(1): 135 - 148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III
Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth
Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Bai, B. He, and E. M. Wilson
Melanoma Antigen Gene Protein MAGE-11 Regulates Androgen Receptor Function by Modulating the Interdomain Interaction
Mol. Cell. Biol., February 15, 2005; 25(4): 1238 - 1257.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Z. Salah, M. Maoz, I. Cohen, G. Pizov, D. Pode, M. S. Runge, and R. Bar-Shavit
Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression
FASEB J, January 1, 2005; 19(1): 62 - 72.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
L. J. Schmidt, H. Murillo, and D. J. Tindall
Gene Expression in Prostate Cancer Cells Treated With the Dual 5 Alpha-Reductase Inhibitor Dutasteride
J Androl, November 1, 2004; 25(6): 944 - 953.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. D. Debes and D. J. Tindall
Mechanisms of Androgen-Refractory Prostate Cancer
N. Engl. J. Med., October 7, 2004; 351(15): 1488 - 1490.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
G. Buchanan, M. Yang, A. Cheong, J. M. Harris, R. A. Irvine, P. F. Lambert, N. L. Moore, M. Raynor, P. J. Neufing, G. A. Coetzee, et al.
Structural and functional consequences of glutamine tract variation in the androgen receptor
Hum. Mol. Genet., August 15, 2004; 13(16): 1677 - 1692.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. N. Papandreou and C. J. Logothetis
Bortezomib as a Potential Treatment for Prostate Cancer
Cancer Res., August 1, 2004; 64(15): 5036 - 5043.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Wang, J. R. Theriault, H. He, J. Gong, and S. K. Calderwood
Expression of a Dominant Negative Heat Shock Factor-1 Construct Inhibits Aneuploidy in Prostate Carcinoma Cells*
J. Biol. Chem., July 30, 2004; 279(31): 32651 - 32659.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Cheng, D. Wang, Z. Wang, and E. T. H. Yeh
SENP1 Enhances Androgen Receptor-Dependent Transcription through Desumoylation of Histone Deacetylase 1
Mol. Cell. Biol., July 1, 2004; 24(13): 6021 - 6028.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X. Liao, J. B. Thrasher, J. Holzbeierlein, S. Stanley, and B. Li
Glycogen Synthase Kinase-3{beta} Activity Is Required for Androgen-Stimulated Gene Expression in Prostate Cancer
Endocrinology, June 1, 2004; 145(6): 2941 - 2949.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Sivashanmugam, L. Tang, and Y. Daaka
Interleukin 6 Mediates the Lysophosphatidic Acid-regulated Cross-talk between Stromal and Epithelial Prostate Cancer Cells
J. Biol. Chem., May 14, 2004; 279(20): 21154 - 21159.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Shukla and S. Gupta
Suppression of Constitutive and Tumor Necrosis Factor {alpha}-Induced Nuclear Factor (NF)-{kappa}B Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF-{kappa}B-Responsive Genes
Clin. Cancer Res., May 1, 2004; 10(9): 3169 - 3178.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. P. Paronetto, D. Farini, I. Sammarco, G. Maturo, G. Vespasiani, R. Geremia, P. Rossi, and C. Sette
Expression of a Truncated Form of the c-Kit Tyrosine Kinase Receptor and Activation of Src Kinase in Human Prostatic Cancer
Am. J. Pathol., April 1, 2004; 164(4): 1243 - 1251.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Rahman, H. Miyamoto, and C. Chang
Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications
Clin. Cancer Res., April 1, 2004; 10(7): 2208 - 2219.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
Y. Daaka
G Proteins in Cancer: The Prostate Cancer Paradigm
Sci. Signal., January 20, 2004; 2004(216): re2 - re2.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French
The Androgen Axis in Recurrent Prostate Cancer
Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Debes, T. J. Sebo, C. M. Lohse, L. M. Murphy, D. A. L. Haugen, and D. J. Tindall
p300 in Prostate Cancer Proliferation and Progression
Cancer Res., November 15, 2003; 63(22): 7638 - 7640.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Uemura, H. Ishiguro, N. Nakaigawa, Y. Nagashima, Y. Miyoshi, K. Fujinami, A. Sakaguchi, and Y. Kubota
Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor
Mol. Cancer Ther., November 1, 2003; 2(11): 1139 - 1147.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. Bookout, A. E. Finney, R. Guo, K. Peppel, W. J. Koch, and Y. Daaka
Targeting G{beta}{gamma} Signaling to Inhibit Prostate Tumor Formation and Growth
J. Biol. Chem., September 26, 2003; 278(39): 37569 - 37573.
[Abstract] [Full Text] [PDF]